Evidence map›Paper›PMID 32213570›Full record

ReviewJournal of neurology, neurosurgery, and psychiatry2020

Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management.

John O'Brien, John Paul Taylor, Clive Ballard, Roger A Barker, Clare Bradley, Alistair Burns, Daniel Collerton, Sonali Dave, Rob Dudley, Paul Francis and 17 more

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Journal of neurology, neurosurgery, and psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05483036 (Perception in Parkinson's Disease), which is not on this map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05483036 completednot on this mapstarted 2022, after this paper: background citation

Perception in Parkinson's Disease

TypeobservationalSponsorBoston University Charles River CampusRan2022 to 2025Enrolled54ConditionsParkinson's Disease, Perception, Visual Hallucination
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Charles Bonnet syndrome in patients referred for cataract surgery.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Charles Bonnet Syndrome associated with unilateral vision loss: A new diagnostic perspective.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025
    Review
  19. Archives of disease in childhood · 2025
    Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 15 institutions in 9 countries.

John O'BrienDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK john.obrien@medschl.cam.ac.uk.ORCID 0000-0002-0837-5080
John Paul TaylorTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0001-7958-6558
Clive BallardUniversity of Exeter Medical School, Medical School Building, St Luke's Campus, Exeter, UK.
Roger A BarkerDepartment of Clinical Neurosciences, WT-MRC Cambridge Stem Cell Institute, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.
Clare BradleyHealth Psychology Research Ltd, Egham, Surrey, UK.
Alistair BurnsFaculty of Medical and Human Sciences, The University of Manchester, Manchester, United Kingdom.
Daniel CollertonTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Sonali DaveInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, London, UK.
Rob DudleyGateshead Early Intervention in Psychosis Service, Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust, Gateshead, UK.
Paul FrancisUniversity of Exeter Medical School, Medical School Building, St Luke's Campus, Exeter, UK.
Andrea GibbonsHealth Psychology Research Unit, Royal Holloway University of London, Egham, Surrey, UK.
Kate HarrisDepartment of Clinical Neurosciences, WT-MRC Cambridge Stem Cell Institute, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.ORCID 0000-0002-6683-4337
Vanessa LawrenceInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, London, UK.
Iracema LeroiGlobal Brain Health Institute, Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland.
Ian McKeithTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Michel MichaelidesMoorfields Eye Hospital NHS Foundation Trust, London, UK.
Chaitali NaikMoorfields Eye Hospital NHS Foundation Trust, London, UK.
Claire O'CallaghanBrain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Kirsty OlsenTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Marco OnofrjClinical Neurologica, Dipartimento di Neuroscienze, Imaging e Scienze Cliniche, Università G.D'Annunzio, Chieti-Pescara, Italy.
Rebecca PintoInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, London, UK.
Gregor RussellBradford District Care NHS Foundation Trust, Lynfield Mount Hospital, Bradford, UK.
Peter SwannDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.
Alan ThomasTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Prabitha UrwylerGerontechnology and Rehabilitation Group, ARTORG Center for Biomedical Engineering Research, University of Bern, Bern, Switzerland.
Rimona Sharon WeilDementia Research Centre, University College London, London, UK.ORCID 0000-0002-5092-6325
Dominic FfytcheInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, London, UK.ORCID 0000-0002-4214-9642
Clinical Research Institute · USKing's College London · GBMoorfields Eye Hospital NHS Foundation Trust · GBRoyal Holloway University of London · GBUniversity of Cambridge · GBWellcome/MRC Cambridge Stem Cell Institute · GBBradford District Care NHS Foundation Trust · GBCumbria Northumberland Tyne and Wear NHS Foundation Trust · GBThe University of Sydney · AUTrinity College Dublin · IEUK Dementia Research Institute · GBUniversity of Bern · CHUniversity of Chieti-Pescara · ITUniversity of Exeter · GBUniversity of Manchester · GB

Funding

Wellcome Trust 205167/Z/16/Z
6 · The paper itself

Abstract

Visual hallucinations are common in older people and are especially associated with ophthalmological and neurological disorders, including dementia and Parkinson's disease. Uncertainties remain whether there is a single underlying mechanism for visual hallucinations or they have different disease-dependent causes. However, irrespective of mechanism, visual hallucinations are difficult to treat. The National Institute for Health Research (NIHR) funded a research programme to investigate visual hallucinations in the key and high burden areas of eye disease, dementia and Parkinson's disease, culminating in a workshop to develop a unified framework for their clinical management. Here we summarise the evidence base, current practice and consensus guidelines that emerged from the workshop.Irrespective of clinical condition, case ascertainment strategies are required to overcome reporting stigma. Once hallucinations are identified, physical, cognitive and ophthalmological health should be reviewed, with education and self-help techniques provided. Not all hallucinations require intervention but for those that are clinically significant, current evidence supports pharmacological modification of cholinergic, GABAergic, serotonergic or dopaminergic systems, or reduction of cortical excitability. A broad treatment perspective is needed, including carer support. Despite their frequency and clinical significance, there is a paucity of randomised, placebo-controlled clinical trial evidence where the primary outcome is an improvement in visual hallucinations. Key areas for future research include the development of valid and reliable assessment tools for use in mechanistic studies and clinical trials, transdiagnostic studies of shared and distinct mechanisms and when and how to treat visual hallucinations.

Indexed as

DementiaEye DiseasesHallucinationsHumansNervous System DiseasesParkinson Diseasedementiahallucinationsparkinson's disease

Identifiers

PMID32213570
PMCPMC7231441
OpenAlexW3013612297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.